DK0517145T3 - Krystallinske oxathiolanderivater - Google Patents

Krystallinske oxathiolanderivater

Info

Publication number
DK0517145T3
DK0517145T3 DK92109221T DK92109221T DK0517145T3 DK 0517145 T3 DK0517145 T3 DK 0517145T3 DK 92109221 T DK92109221 T DK 92109221T DK 92109221 T DK92109221 T DK 92109221T DK 0517145 T3 DK0517145 T3 DK 0517145T3
Authority
DK
Denmark
Prior art keywords
oxathioland
crystalline
derivatives
oxathioland derivatives
crystalline oxathioland
Prior art date
Application number
DK92109221T
Other languages
Danish (da)
English (en)
Inventor
Paul Ravenscroft
Tony Gordon Roberts
Paul Evans
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10696001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0517145(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK0517145T3 publication Critical patent/DK0517145T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Secondary Cells (AREA)
DK92109221T 1991-06-03 1992-06-02 Krystallinske oxathiolanderivater DK0517145T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919111902A GB9111902D0 (en) 1991-06-03 1991-06-03 Chemical compounds

Publications (1)

Publication Number Publication Date
DK0517145T3 true DK0517145T3 (da) 2002-05-06

Family

ID=10696001

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92109221T DK0517145T3 (da) 1991-06-03 1992-06-02 Krystallinske oxathiolanderivater

Country Status (31)

Country Link
US (1) US5905082A (fr)
EP (2) EP1099700A1 (fr)
JP (1) JP2851480B2 (fr)
KR (1) KR100244008B1 (fr)
AP (1) AP300A (fr)
AT (1) ATE212630T1 (fr)
AU (2) AU656379B2 (fr)
BG (1) BG60914B1 (fr)
CA (2) CA2311988C (fr)
CZ (1) CZ284513B6 (fr)
DE (1) DE69232387T2 (fr)
DK (1) DK0517145T3 (fr)
ES (1) ES2171158T3 (fr)
GB (1) GB9111902D0 (fr)
GE (1) GEP19991834B (fr)
HK (1) HK1009599A1 (fr)
IE (2) IE921780A1 (fr)
IL (1) IL102073A (fr)
IS (2) IS1867B (fr)
MX (1) MX9202619A (fr)
NO (1) NO301713B1 (fr)
NZ (1) NZ242981A (fr)
OA (1) OA09913A (fr)
PT (1) PT517145E (fr)
RU (1) RU2102393C1 (fr)
SG (1) SG52455A1 (fr)
SK (1) SK281249B6 (fr)
TW (1) TW254939B (fr)
UA (1) UA41265C2 (fr)
WO (1) WO1992021676A1 (fr)
ZA (1) ZA924007B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581979A (en) * 1983-07-01 1986-04-15 Automotive Products Plc Shipping and installation restraining clip for master cylinder input member
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
AU722214B2 (en) 1995-06-07 2000-07-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis B virus activity
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
HUP9903249A3 (en) 1996-06-25 2001-04-28 Glaxo Group Ltd Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
AU2002335489B2 (en) * 2001-03-01 2008-06-05 Abbott Laboratories Polymorphic and other crystalline forms of cis-FTC
CA2351049C (fr) 2001-06-18 2007-03-13 Brantford Chemicals Inc. Procede pour separer des nucleosides cis-1,3-oxathiolaniques recherches de leurs isomeres trans non desires
WO2003027106A1 (fr) * 2001-09-25 2003-04-03 Cadila Healthcar Limited Procede de preparation de polymorphes ii cristallins de lamivudine
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
ES2286471T3 (es) * 2002-11-08 2007-12-01 Glaxo Group Limited Composiciones farmaceuticas antivirales.
US20040224917A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
EP1809662B1 (fr) * 2004-11-10 2008-11-26 Novartis Vaccines and Diagnostics, Inc. Interferon beta desamine
US20060242012A1 (en) * 2005-04-22 2006-10-26 Sumit Agarwal Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
DE602007009957D1 (de) * 2006-04-18 2010-12-02 Lupin Ltd Neue kristalline form von lamivudin
WO2009031026A2 (fr) * 2007-09-06 2009-03-12 Combino Pharm, S.L. Nouvelles compositions pharmaceutiques
WO2009037538A2 (fr) * 2007-09-17 2009-03-26 Aurobindo Pharma Ltd Procédé de préparation de lamivudine de forme i
US20100324290A1 (en) * 2007-11-29 2010-12-23 Ranbaxy Laboratories Limited Crystalline form i of lamivudine and its preparation
CN101918416A (zh) * 2007-11-29 2010-12-15 兰贝克赛实验室有限公司 制备取代的1,3-氧硫杂环戊烷,尤其是拉米夫定的方法和中间体
EP2225232B1 (fr) * 2007-11-29 2012-09-26 Ranbaxy Laboratories Limited Procédé de préparation de 1,3-oxathiolanes substitués
WO2009127996A1 (fr) * 2008-04-17 2009-10-22 Ranbaxy Laboratories Limited Nouvelle forme cristalline de lamivudine
US8536151B2 (en) * 2008-09-01 2013-09-17 Hetero Research Foundation Process for preparing lamivudine polymorph form
US20110288298A1 (en) * 2008-11-12 2011-11-24 Lupin Limited novel polymorph of emtricitabine and a process for preparing of the same
CN101531656B (zh) * 2009-03-24 2010-12-08 福建广生堂药业有限公司 拉米夫定晶型及其制备方法
CN101993439B (zh) * 2009-03-24 2013-04-24 福建广生堂药业股份有限公司 拉米夫定晶型及其制备方法
WO2010137027A1 (fr) * 2009-05-27 2010-12-02 Hetero Research Foundation Formes pharmaceutiques solides de lamivudine s'administrant par voie orale
EP2454244B1 (fr) 2009-07-15 2013-06-26 Lupin Limited Procédé perfectionné de préparation d'efavirenz
EP2488516B1 (fr) 2009-10-14 2015-04-01 Mylan Laboratories Limited Procédé pour la préparation de lamivudine et nouveaux sels dans sa fabrication
ES2688925T3 (es) 2010-01-27 2018-11-07 Viiv Healthcare Company Tratamiento antiviral
US20120295930A1 (en) * 2010-02-03 2012-11-22 Shankar Rama Novel process for the preparation of cis-nucleoside derivative
AU2011215878A1 (en) * 2010-02-12 2012-08-09 Merck Sharp & Dohme Corp. Preparation of lamivudine Form I
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
US20130296562A1 (en) 2011-08-05 2013-11-07 Lupin Limited Stereoselective process for preparation of 1,3-oxathiolane nucleosides
WO2013168066A1 (fr) 2012-05-05 2013-11-14 Lupin Limited Procédé amélioré de fabrication de lamivudine de forme i
CN114099454B (zh) * 2020-08-31 2023-06-27 长春海悦药业股份有限公司 一种拉米夫定片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides

Also Published As

Publication number Publication date
EP0517145A1 (fr) 1992-12-09
AU1881092A (en) 1993-01-08
IS1867B (is) 2003-05-02
AP9200395A0 (en) 1992-07-31
ATE212630T1 (de) 2002-02-15
IL102073A (en) 1996-05-14
US5905082A (en) 1999-05-18
CA2311988C (fr) 2005-11-15
EP1099700A1 (fr) 2001-05-16
IS3873A (is) 1992-12-04
WO1992021676A1 (fr) 1992-12-10
IS4268A (is) 1995-02-27
BG98254A (bg) 1994-07-29
AU656379B2 (en) 1995-02-02
DE69232387D1 (de) 2002-03-14
RU2102393C1 (ru) 1998-01-20
GB9111902D0 (en) 1991-07-24
NO301713B1 (no) 1997-12-01
SK281249B6 (sk) 2001-01-18
KR100244008B1 (ko) 2000-03-02
AU1736192A (en) 1993-03-11
JPH06211848A (ja) 1994-08-02
IL102073A0 (en) 1993-01-14
CA2311988A1 (fr) 1992-12-04
JP2851480B2 (ja) 1999-01-27
EP0517145B1 (fr) 2002-01-30
NO922182L (no) 1992-12-04
IE921780A1 (en) 1992-12-16
CA2070230C (fr) 2004-08-03
BG60914B1 (bg) 1996-06-28
UA41265C2 (uk) 2001-09-17
CA2070230A1 (fr) 1992-12-04
TW254939B (fr) 1995-08-21
OA09913A (en) 1994-09-15
ES2171158T3 (es) 2002-09-01
IE20020782A1 (en) 2003-04-02
KR930000511A (ko) 1993-01-15
SK125793A3 (en) 1994-11-09
GEP19991834B (en) 1999-11-05
NZ242981A (en) 1994-04-27
CZ284513B6 (cs) 1998-12-16
NO922182D0 (no) 1992-06-02
MX9202619A (es) 1992-12-01
AP300A (en) 1994-01-20
CZ261293A3 (en) 1994-04-13
ZA924007B (en) 1993-04-28
DE69232387T2 (de) 2002-09-26
PT517145E (pt) 2002-07-31
SG52455A1 (en) 1998-09-28
HK1009599A1 (en) 1999-06-04

Similar Documents

Publication Publication Date Title
ATE212630T1 (de) Kristallinische oxathiolanderivate
DE69208877D1 (de) Chinuclidinderivate
FI925763A0 (fi) Fungicida 2-imidazolin-5-on- och 2-imidazolin-5-tionderivat
TR26336A (tr) SüBSTITüE EDILMIS PIRAZOLIN TüREVLERI
NO923580D0 (no) Substituerte imidazolylpropensyrederivater
FI923552A (fi) Smaelt kristalliserad xylitol
FI933542A0 (fi) Blekning av lignocellulosamaterial med aktiverat syre
DE69216260D1 (de) Piperidinderivate
NO920420L (no) 3-quinuklidin-derivater
FI922385A (fi) Foerfarande foer reglering av ensymaktiviter med aedelgaser
FI921811A (fi) Foerfarande foer framstaellning av maongskiktspappers- och maongskiktspapprodukter med oekad styvhet
FI88322B (fi) Med ledbommar foersedd arbetsmaskin
FI925469A (fi) Tiazolylsubstituerade kinolylymetoxifenylaettiksyraderivat
FI925416A0 (fi) Framstaellning av metalloxidsoler med elektrolys
FI934083A0 (fi) Foerfarande foer behandling av bomullshaltiga vaevnader med cellulas
MX9206710A (es) Derivados de piridinol
BR9005812A (pt) Poliimidossiloxanos cristalinos
FI912080A (fi) Lagringslaoda foersedd med en gavelvaeggen slutande genomsynlig klaffskiva
FI920393A (fi) Radio- och landfoerbindelsetelefoner med hands-free-funktion
NO924543D0 (no) Maktocykliske laktamderivater
DE69211197D1 (de) 1-Hydroxyvitamin D-Derivate
KR930702353A (ko) 2- 카르바페넴 유도체
FI933760A0 (fi) Maerkning av proteiner med teknetium-99m
FI920885A (fi) Paovisande av bakterier med bistaond av en nukleinsyraamplifikation
DE69227554T2 (de) Indolinospirobenzopyran-derivate